User profiles for D. L. Gibbons
 | Don L. Gibbons, MD, PhDProfessor, Dept. of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer … Verified email at mdanderson.org Cited by 18865 |
Treatment of non–small-cell lung cancer with erlotinib or gefitinib
VD Cataldo, DL Gibbons, R Pérez-Soler… - … England Journal of …, 2011 - Mass Medical Soc
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
Smoking, p53 mutation, and lung cancer
DL Gibbons, LA Byers, JM Kurie - Molecular cancer research, 2014 - AACR
This issue marks the 50th anniversary of the release of the US Surgeon General's Report on
Smoking and Health. Perhaps no other singular event has done more to highlight the effects …
Smoking and Health. Perhaps no other singular event has done more to highlight the effects …
[HTML][HTML] The fibrotic tumor stroma
M Yamauchi, TH Barker, DL Gibbons… - The Journal of clinical …, 2018 - Am Soc Clin Investig
… Download citation information … Conflict of interest: DL Gibbons received laboratory
research funding from Janssen Research and Development. … Download citation information …
research funding from Janssen Research and Development. … Download citation information …
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line …
…, F Skoulidis, LE Gaspar, DL Gibbons… - The lancet …, 2016 - thelancet.com
… function included the following: absolute neutrophil count 1·5 cells × 10 9 /L, platelet count
100 cells × 10 9 /L, white blood count 3 cells × 10 9 /L, and haemoglobin 9 g/dL or higher …
100 cells × 10 9 /L, white blood count 3 cells × 10 9 /L, and haemoglobin 9 g/dL or higher …
[HTML][HTML] Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi …
…, LE Gaspar, JW Welsh, DL Gibbons… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Our previously published findings reported that local consolidative therapy (LCT)
with radiotherapy or surgery improved progression-free survival (PFS) and delayed new …
with radiotherapy or surgery improved progression-free survival (PFS) and delayed new …
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
…, II Wistuba, SG Swisher, JJ Lee, DL Gibbons… - Nature medicine, 2021 - nature.com
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small
cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment …
cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment …
[HTML][HTML] Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Immunosuppression of tumour-infiltrating lymphocytes (TIL) is a common feature of advanced
cancer, but its biological basis has remained obscure. We demonstrate here a molecular …
cancer, but its biological basis has remained obscure. We demonstrate here a molecular …
[HTML][HTML] Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
…, AA Vaporciyan, HY Lin, J Wang, DL Gibbons… - Nature medicine, 2023 - nature.com
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT)
induce greater pathologic response rates than CT alone in patients with operable non-small …
induce greater pathologic response rates than CT alone in patients with operable non-small …
Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer
Our results define previously unrecognized immunomodulatory functions of DDR inhibitors
and suggest that adding PARP or CHK1 inhibitors to ICB may enhance treatment efficacy in …
and suggest that adding PARP or CHK1 inhibitors to ICB may enhance treatment efficacy in …
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression
DL Gibbons, W Lin, CJ Creighton, ZH Rizvi… - Genes & …, 2009 - genesdev.cshlp.org
Metastatic disease is a primary cause of cancer-related death, and factors governing tumor
cell metastasis have not been fully elucidated. Here, we address this question by using tumor …
cell metastasis have not been fully elucidated. Here, we address this question by using tumor …